Chemotherapy in soft tissue sarcomas;La chimiothérapie des sarcomes des tissus mous

Cancer/Radiotherapie

Volumn 10, Issue 1-2, 2006, Pages 68-71

  Zelek, L ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Adjuvant treatment; Chemotherapy; Metastasis; Soft tissue sarcomas

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; DOXORUBICIN; ERLOTINIB; IFOSFAMIDE; IMATINIB; TRABECTEDIN; UNCLASSIFIED DRUG; VACIZUMAB;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; HUMAN; LIMB TUMOR; PRIORITY JOURNAL; REVIEW; SOFT TISSUE SARCOMA;

EID: 33645316844     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2005.11.003     Document Type: Short Survey

References (19)

1. G. Blackledge, A. van Oosterom, H.T. Mouridsen, V. Bramwell, A. Santoro, and J. Verweij The place of chemotherapy in the management of soft tissue sarcoma: experiences of the EORTC soft tissue and bone sarcoma group Clin. Oncol. (R. Coll. Radiol.) 1 1989 106 109
2. P.G. Casali, and P. Picci Adjuvant chemotherapy for soft tissue sarcoma Curr. Opin. Oncol. 2005 17 2005 361 365
3. M.A. Clark, C. Fisher, I. Judson, and J.M. Thomas Soft-Tissue sarcomas in adults N. Engl. J. Med. 353 2005 701 711
4. J.N. Cormier, X. Huang, Y. Xing, P.F. Thall, X. Wang, and R.S. Benjamin Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy associated outcomes J. Clin. Oncol. 22 2004 4567 4574
5. D.R. D'Adamo, S. Anderson, J. Albritton, J. Yamada, E. Riedel, and J. Scheu KYamada Cardiac toxicity in a phase II study of doxorubicin (DOX) and bevacizumab (BEV) for patients (pts) with metastatic soft-tissue sarcomas (STS) Proc. Annu. Meet. Am. Soc. Clin. Oncol. 14 2004 817 (abs 9012)
6. G.D. Demetri, M. von Mehren, C.D. Blanke, A.D. Van den Abbeele, B. Eisenberg, and P.J. Roberts Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N. Engl. J. Med. 347 2002 472 480
7. R. Fata, E. O'Reilly, D. Ilson, D. Pfister, D. Leffel, and D.P. Kelsen Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face Cancer 86 1999 2034 2037
8. S. Frustaci, F. Gherlinzoni, A. De Paoli, M. Bonetti, A. Azzarelli, and A. Comandone Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial J. Clin. Oncol. 19 2001 1238 1247
9. S.R. Grobmyer, R.G. Maki, G.D. Demetri, M. Mazumdar, E. Riedel, and M.F. Brennan Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma Ann. Oncol. 15 2004 1667 1672
10. M.L. Hensley, R. Maki, E. Venkatraman, G. Geller, M. Lovegren, and C. Aghajanian Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial J. Clin. Oncol. 20 2002 2824 2831
11. I. Judson, J.A. Radford, M. Harris, J.Y. Blay, Q. Van Hoesel, and A. le Cesne Randomized phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) vs doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC soft tissu and bone sarcoma group Eur. J. Cancer 37 2001 870 877
12. W.M. Mendenhall, R.A. Zlotecki, S.N. Hochwald, A.W. Hemming, S.R. Grobmyer, and W.G. Cance Retroperitoneal soft tissue sracoma Cancer 104 2005 669 675
13. O.S. Nielsen, P. Dombernovsky, H. Mouridsen, D. Crowther, J. Verweij, and J. Buesa High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group Br. J. Cancer 78 1998 1634 1639
14. G. Rosen, C. Forscher, S. Lowenbraun, F. Eilber, J. Eckardt, and C. Holmes Synovial sarcoma. Uniform response of metastases to high-dose ifosfamide Cancer 15 1994 2506 2511
15. Sarcoma meta-analysis collaboration Adjuvant chemotherapy for adult soft-tissue sarcomas of the extremities and girdles: meta-analysis of individual data Lancet 350 1997 1647 1654
16. A.T. van Ooosterom, H.T. Mouridsen, O.S. Nielsen, P. Dombernowsky, K. Krzemieniecki, and I. Judson Results of randomised studies of the EORTC soft tissue and bone sarcoma group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients Eur. J. Cancer 38 2002 2397 2406
17. J. Verweij, S.M. Lee, W. Ruka, J. Buesa, R. Coleman, and R. van Hoessel Randomised phase II study of docetaxel vs doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group J. Clin. Oncol. 18 2000 2081 2086
18. J. Verweij, H.T. Mouridsen, O.S. Nielsen, P.J. Woll, R. Somers, and A.T. van Oosterom The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of wiev Crit. Rev. Oncol. Hematol. 20 1995 193 201
19. A. Yovine, M. Riofrio, J.Y. Blay, E. Brain, J. Alexandre, and C. Kahatt Phase II study of ecteinascidin-743 in advanced pertreated soft tissue sarcoma patients J. Clin. Oncol. 22 2004 890 899